Close Menu

Share with your friends


Respiri Limited (ASX: RSH)

The recent spate of weather related asthma deaths brought home how vulnerable many people can be when faced with life threatening asthma related symptoms.

‘Thunderstorm asthma’ has increased awareness, however the rate of death caused by asthma has remained unchanged since 2003 despite all the advances in technology over past 14 years.

One ASX listed medtech company is looking to reverse these rates and make a real impact on the global asthma market via its suite of monitoring and management products.

This company has developed a world leading, comprehensive monitoring and management system that measures a patient’s wheezing.

Its consumer product could be considered as a “digital stethoscope”, connected to your smartphone via Bluetooth.

Offering a real time, continuous data stream for patient monitoring, this medical device stock is leveraged to the explosion in wearable health and fitness devices that is taking place.

There is a clear and growing addressable market for a company that could completely invigorate asthma monitoring products. This market is estimated to reach $47 billion this year, with over 330 million people globally suffering from asthma alone.

If it can have the impact it expects, it would potentially be looking to follow in the footsteps of other medtech companies that have attracted large valuations via attractive mergers and acquisitions deals.

The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

This company is making large leaps towards commercialisation and is directing its focus on securing partnership agreements to help launch a new generation of its continuous monitoring system in a large overseas market.

Currently valued by the market at a modest $16.4 million, if this company can fill the gap in the market for comprehensive and connected asthma monitoring systems, it would go a long way to reducing the impact on a crippling medical problem. 


Latest Article

A Breath of Fresh Air: ASX MedTech Company on Cusp of Sales

Asthma kills. We’re not here to stoke fear, but it’s no exaggeration that the consequences can be catastrophic if asthma is not adequately monitored and proactively treated. Asthma sufferers have sensitive airways which react to a wide and varied range of emotional, physiological and environmental triggers. Once triggered, an asthma attack involves inflammation of the lining of the airways, the tightening of muscles around the airways, and the excess production of mucus.

Apr 10, 2017 Continue Reading

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

[gravityform id="31" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="31" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.